Press Release: aap reports strong Q4/2014 sales growth in trauma; annual sales reach EUR 31.7 million driven by a 63% sales growth in LOQTEQ(R)

aap Implantate AG / aap reports strong Q4/2014 sales growth in trauma; annual sales reach EUR 31.7 million driven by a 63% sales growth in LOQTEQ(R) . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) generated, according to preliminary figures, sales of EUR 8.6 million in the fourth quarter of 2014. In full year 2014 the company reported sales of EUR 31.7 million thereby achieving a result within the target range of EUR 30 million to EUR 34 million communicated in October 2014. Of these EUR 31.7 million an amount of EUR 30.7 million is attributable to the continued operations (aap Implantate AG excluding EMCM B.V.). As a result of the sale of EMCM B.V. on February 28, 2014, the sales figures for the financial year 2014 include sales from EMCM for January and February totaling EUR 1.0 million.

Sales in EUR million Q4/2014 Q4/2013 Change Trauma 3.9 3.1 25% thereof LOQTEQ(R) 3.0 1.9 56% Biomaterials 3.7 6.0 -38% Projects 0.9 0.4 136% Other 0.1 0.1 13% Sales from continued operations 8.6 9.6 -10%

Sales in EUR million FY 2014 FY 2013 Change Trauma 12.3 9.6 27% thereof LOQTEQ(R) 8.2 5.0 63% Biomaterials 16.4 15.0 10% Projects 1.2 2.8 -58% Other 0.8 1.2 -31% Sales from continued operations 30.7 28.6 7% Sales from discontinued operations 1.0* 11.4*(2) -92% Sales total 31.7 40.0 -21%

* Sales revenues EMCM B.V. 01-02/2014: EUR 1.2 million less consolidation effects (EUR 0.2 million)

*(2) Sales revenues EMCM B.V. 01-12/2013: EUR 12.3 million less consolidation effects (EUR 0.9 million)

The positive sales development was particularly driven by the trauma business. This underlines the strategic alignment of the management board transforming aap Implantate AG in a leading European trauma company. Sales in the trauma business increased in the fourth quarter of 2014 compared to the corresponding period in the last year by 25% to EUR 3.9 million (Q4/2013: EUR 3.1 million). In full year 2014 the company reported sales of EUR 12.3 million in the trauma business, corresponding to a growth rate of 27% with respect to the result in the previous year (FY 2013: EUR 9.6 million).

Considering the sales in the trauma business more detailed, the development of the LOQTEQ(R) product family has to be emphasized particularly. Here the company was able to increase sales in the fourth quarter of 2014 over the corresponding period in the previous year (Q4/2014: EUR 1.9 million) by 56% to EUR 3.0 million. In full year 2014 aap Implantate AG realized a significant sales growth of 63% with LOQTEQ(R) as well reaching a result of EUR 8.2 million (FY 2013: EUR 5.0 million). The positive sales development of LOQTEQ(R) demonstrates that the IP protected product family is increasingly well established at the market and has a strong appeal among several customers. All in all the growth dynamic in the fourth quarter of 2014 and in the full year 2014 underlines the successful implementation of the strategy sustainably aligning aap Implantate AG on the trauma business.

In its biomaterials business aap Implantate AG reported a sales growth of 10% to EUR 16.4 million (FY 2013: EUR 15.0 million) in financial year 2014 compared to the previous year. The decline in the fourth quarter of 2014 to EUR 3.7 million results from extensive initial deliveries in the corresponding quarter of the previous year.

Furthermore the company still holds intensive talks with selected strategic investors and private equity investors on a possible transaction for aap Biomaterials GmbH (bone cements and mixing systems and biomaterials). The objective is still to conclude a definitive agreement in the first quarter of 2015 and thereby to transform aap Implantate AG into a company that is solely active in the trauma business.

The preliminary results contained in this press release are unaudited and based on management's initial analysis of operations for the periods ended December 31, 2014, and are therefore subject to change. aap Implantate AG plans to announce its final, audited results of the financial year 2014 on March 31, 2015.

We will give a first forecast for the financial year 2015 and the first quarter of 2015 as well as the evaluation of the management agenda 2014 within a separate release at the beginning of February 2015.

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1886332

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   January 12, 2015 15:48 ET (20:48 GMT)- - 03 48 PM EST 01-12-15